A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...

Proceeds to support registration-enabling trials, DOMMINO-1 and DOMMINO-2, and continued development of the first-in-class p300/CBP inhibitor Financing led by Venrock Healthcare Capital Partners, with ...

CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Elouise Wrisper’s cancer journey began with persistent back pain. It was 2021, and the retired teacher, who was active in ...

Elranatamab (Elrexfio; Pfizer) achieved the primary endpoint of progression-free survival (PFS) at a prespecified interim ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

While earlier-line BCMA CAR T-cell therapy in multiple myeloma offers superior efficacy and longer treatment-free survival, careful monitoring and further research are needed to manage rare but ...

Right now, CELMoDs are being studied in patients whose cancer has returned after prior treatment, but their role could expand ...

The treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for patients with relapsed or refractory disease. At this year's American Society of ...

The study evaluated the efficacy and safety of the investigational immunotherapy combination of TECVAYLI ® plus DARZALEX FASPRO ® versus DARZALEX FASPRO ® and dexamethasone with either pomalidomide or ...